Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

812 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Walker BA, et al. Among authors: johnson dc. J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282654 Free PMC article. Clinical Trial.
APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.
Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. Walker BA, et al. Among authors: johnson dc. Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997. Nat Commun. 2015. PMID: 25904160 Free PMC article.
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF. Shah V, et al. Among authors: johnson dc. Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6. Leukemia. 2018. PMID: 28584253 Free PMC article.
A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.
Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. Walker BA, et al. Among authors: johnson dc. Blood. 2010 Oct 14;116(15):e56-65. doi: 10.1182/blood-2010-04-279596. Epub 2010 Jul 8. Blood. 2010. PMID: 20616218 Free article. Clinical Trial.
The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.
Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ. Pawlyn C, et al. Among authors: johnson dc. Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. doi: 10.1158/1078-0432.CCR-15-1790. Epub 2016 May 27. Clin Cancer Res. 2016. PMID: 27235425 Free PMC article. Clinical Trial.
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG. Jones JR, et al. Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7. Haematologica. 2019. PMID: 30733268 Free PMC article. Clinical Trial.
Neutral tumor evolution in myeloma is associated with poor prognosis.
Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF. Johnson DC, et al. Blood. 2017 Oct 5;130(14):1639-1643. doi: 10.1182/blood-2016-11-750612. Epub 2017 Aug 21. Blood. 2017. PMID: 28827410 Free PMC article. Clinical Trial.
Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Dickens NJ, et al. Among authors: johnson dc. Clin Cancer Res. 2010 Mar 15;16(6):1856-64. doi: 10.1158/1078-0432.CCR-09-2831. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215539 Free PMC article. Clinical Trial.
812 results